In only a few years, the Western Atrial Fibrillation Symposium has become a must-attend event for hundreds of cardiologists, physicians and others interested in the pathophysiology, diagnosis, and treatment of patients with atrial fibrillation. The third annual conference, which will take place February 26-27 in Park City, Utah, has attracted a world-class faculty that includes physicians from leading medical centers in the U.S., Belgium, Canada, France, Germany and Japan.

The speakers will provide updates on new research and its implications, including these topics on three notable clinical trials:
• The Athena Trial: A Turning Point in Atrial Fibrillation Management for Patients with Normal Hearts?
• The Castle-AF Trial and its Impact on Atrial Fibrillation Management for Patients with Heart Failure
• Impact of the RE-LY Trials on Anticoagulation Strategies: Are We Closing the Coumadin Clinics?

The second day of the symposium will focus on atrial fibrillation ablation and new solutions for AF treatment and management. Sessions will include several presentations on novel MRI techniques for the management of AF.

Physicians who attend this educational activity can earn a maximum of 10 AMA PRA Category 1 Credits™. The symposium is also open to nurse practitioners, nurses, cardiovascular technologists, residents and students. For more information, including how to register and reserve a room at the Park City Marriott, visit www.westernatrialfibrillation.com/.

In next month’s blog, I’ll share with you highlights from the conference.

Nassir F. Marrouche, MD is the Executive Director of the Comprehensive Arrhythmia Research & Management Center, Director of Electrophysiology Laboratories, and Director of the Atrial Fibrillation Program at the University of Utah School of Medicine, Division of Cardiology.